Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISCADOR M is a fermented aqueous extract of European mistletoe (Viscum album L.) grown on apple trees (Malus domestica). [4] It is developed and marketed by Iscador AG as an anthroposophic medicine. [1, 7] The active components are a complex mixture of substances, with mistletoe lectins and viscotoxins being the most studied bioactive components. [2, 3] ISCADOR M is used as a complementary therapy in oncology for various malignancies, including breast cancer, melanoma, and colorectal cancer. [14] It is administered via subcutaneous injection and is believed to exert its effects through immunomodulation, such as stimulating various immune cells (e.g., T cells, NK cells), and by direct cytotoxicity, including the induction of apoptosis in cancer cells. [2, 3, 9] The product is part of a series of Iscador preparations that are differentiated by the host tree from which the mistletoe is harvested. [11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Iscador M.